Literature DB >> 8554203

Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention.

P J Savage1.   

Abstract

Cardiovascular disease is a major causes of morbidity and mortality in patients with non-insulin-dependent diabetes mellitus (NIDDM). With an increase in the number of older diabetic persons, an increase in U.S. minority populations with high rates of diabetes, and the proven success of new methods to reduce microvascular complications, the importance of diabetic macrovascular complications will increase. The relative effectiveness of different treatments to reduce the incidence of diabetic cardiovascular complications is poorly understood. In addition to relative efficacy, issues related to patient burden and the economic cost of different treatments must be considered. Some of the information needed to improve therapy therapy will be available soon from ongoing clinical trials. Obtaining definitive answers to other questions, especially those related to the relative benefit of intensive glucose level control compared with control of other known cardiovascular disease risk factors, will require additional studies. Although several questions unique to diabetic patients remain unanswered, results of previous clinical trials done among largely nondiabetic participants can be used to develop interim recommendations for cardiovascular disease prevention. Until definitive guidelines for prevention are established, combining aggressive therapy for known cardiovascular disease risk factors with efforts to normalize the glucose level offers the best chance to reduce the higher risk for cardiovascular disease associated with NIDDM.

Entities:  

Mesh:

Year:  1996        PMID: 8554203     DOI: 10.7326/0003-4819-124-1_part_2-199601011-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  19 in total

1.  A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.

Authors:  Erin L St Onge; Carol Anne Motycka; Shannon A Miller
Journal:  P T       Date:  2009-07

Review 2.  Post-transplant hyperlipidaemia.

Authors:  R M Jindal
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

Review 3.  Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

Authors:  L J Scott; C M Spencer
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

Authors:  R E Law; W P Meehan; X P Xi; K Graf; D A Wuthrich; W Coats; D Faxon; W A Hsueh
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  Amelioration of diabetic dyslipidemia by macrocyclic binuclear oxovanadium complex on streptozotocin induced diabetic rats.

Authors:  Balasubramanian Ramachandran; Sorimuthu Subramanian
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

Review 6.  Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.

Authors:  A Evans; A J Krentz
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 7.  Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

8.  Issues and challenges with antithrombotic therapy in diabetic patients with acute coronary syndromes.

Authors:  G W Barsness
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

9.  The kinematic filling efficiency index of the left ventricle: contrasting normal vs. diabetic physiology.

Authors:  Wei Zhang; Charles S Chung; Matt M Riordan; Yue Wu; Leonid Shmuylovich; Sándor J Kovács
Journal:  Ultrasound Med Biol       Date:  2007-05-03       Impact factor: 2.998

Review 10.  [Diabetic complications. Micro and macroangiopathic end-organ damage].

Authors:  U D Lichtenauer; J Seissler; W A Scherbaum
Journal:  Internist (Berl)       Date:  2003-07       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.